📰 Alimera Sciences News
Page 7 - Alimera Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alimera Sciences. Real-time updates on events, politics, business and more.
June 21, 2023
StockNews.com started coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a report released on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Other equities research analysts have also recently issued research reports about the stock. Craig Hallum decreased their target price on shares of Alimera Sciences from […]
June 20, 2023
StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a report published on Saturday. The firm issued a hold rating on the biopharmaceutical company’s stock. A number of other brokerages have also commented on ALIM. Alliance Global Partners upgraded shares of Alimera Sciences from a neutral rating to a buy rating […]
June 17, 2023
Analysts’ new coverage for Saturday, June 17th: StockNews.com started coverage on shares of ATA Creativity Global (NASDAQ:AACG). They issued a sell rating on the stock. StockNews.com initiated coverage on shares of Atlantic American (NASDAQ:AAME). The firm issued a hold rating on the stock. StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS). They issued a […]
June 14, 2023
Alimera Sciences (NASDAQ:ALIM – Get Rating) was upgraded by equities research analysts at Alliance Global Partners from a “neutral” rating to a “buy” rating in a note issued to investors on Monday, The Fly reports. Other research analysts also recently issued research reports about the company. HC Wainwright cut their target price on Alimera Sciences […]
June 14, 2023
Alimera Sciences, Inc. (NASDAQ:ALIM – Get Rating) was the recipient of a significant growth in short interest during the month of May. As of May 31st, there was short interest totalling 791,600 shares, a growth of 3,157.6% from the May 15th total of 24,300 shares. Based on an average daily trading volume, of 606,100 shares, […]
June 13, 2023
Alliance Global Partners upgraded shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) from a neutral rating to a buy rating in a research report report published on Monday, The Fly reports. A number of other research firms have also issued reports on ALIM. Craig Hallum reduced their target price on shares of Alimera Sciences from […]
June 13, 2023
StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research note released on Friday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Other research analysts have also recently issued reports about the stock. Craig Hallum dropped their target price on shares of Alimera Sciences from $18.00 to […]
June 5, 2023
StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research note published on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. A number of other equities analysts have also issued reports on the company. HC Wainwright lowered their price target on Alimera Sciences from $9.00 […]
June 4, 2023
StockNews.com started coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research note issued to investors on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. A number of other research firms have also weighed in on ALIM. Craig Hallum reduced their target price on shares of Alimera […]
May 30, 2023
EyePoint Pharmaceuticals is a $200m market cap biotech focused on eye disease. Read more to see a full investment analysis of EYPT stock.